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Abstract
This study reports the synthesis of a novel conformationally restricted ethylenediamine
scaffold that can be explored for drug discovery. There was significant progress in synthesizing
the target scaffolds, but future studies are needed to finish this synthesis. This potential
ethylenediamine compound may offer new scaffolds for exploration in drug design and orexin
receptor antagonists with improved selectivity for OX1R and OX2R.
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Introduction:
It has been shown that a drug's chemical structure determines its physicochemical
properties, such as its appearance, boiling point, density, and ADME properties1. Therefore,
structural modifications of drugs are likely to alter their interactions with target proteins and
change their pharmaceutical properties such as solubility, metabolism, and pharmacokinetics1.
Conformationally restricted molecules possess structural features that decrease the freedom of
intramolecular motions by holding atoms at well-defined distances and orientations in space2.
The molecule's rigidity may be beneficial for achieving efficient and selective binding to its
biological protein targets in specific regions of space. This is due to the restricted scaffolds
holding nitrogen atoms at an optimal distance so that the nitrogen atoms can achieve efficient
intramolecular interactions with other molecules.
In medicinal chemistry, diamines can be used to evaluate ligands for G-protein coupled
receptors and enzyme inhibitors3. Ethylenediamine is an organic compound used as a building
block to produce many other chemical products such as aminophylline4. Ethylenediamine is a
conformationally flexible bidentate chelating ligand with two nitrogen atoms donating their lone
pairs of electrons. Due to its bifunctional nature, the two amines readily form heterocycles by
reacting to itself5. Today, many drugs on the market have more rigid ethylenediamine units as
building blocks for biologically active molecules4. Figure 1 below illustrates different points at
which this diamine can be restricted. The synthesis of new rigid ethylenediamine scaffolds may
provide templates for new drug designs and show potential for drug design. These scaffolds
permit exploration of stereochemistry and geometry of ethylenediamine to influence drug-target
interactions.
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Figure 1. The ethylenediamine structure can be conformed into different restricted cyclic
structures.
One example of a case where a conformationally restricted diamine was used to improve
the affinity of an enzyme inhibitor is shown in Figure 2. The flexible sulfur-based linker in
BPTES (2) was replaced by a 3-amino-pyrrolidine moiety6 (4).
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Figure 2. Ethylenediamine core showed increased activity compared to the leading known GAC
inhibitor BPTES by 9x fold.
The ethylenediamine structure was investigated as a scaffold during screening for leads to
address different diseases. Inhibition of glutaminase (GAC) is an anticancer target that leads to
the reduction of tumor cells. The GAC inhibitors contain a lipophilic chain that connects two
aromatic heterocycles with an ethylenediamine core structure used for screening and further
optimization (Fig 2). Ligand and lipophilic efficiencies were used as the scoring methods to
measure GAC inhibitors’ potency and physicochemical properties. This leads to improved cellbased ligand efficacy (LE), lipophilic efficiency (LipE), and GAC IC50 compared to the known
GAC inhibitor BPTES6 (2). Both isomers of the amino pyrrolidine were evaluated for their
stereoselectivity and showed that the one enantiomer isomer, 4 has a better inhibition than the
other enantiomer 5. Two lead structure designs from the vital feature scaffold went through
further optimizations, which increased the activity of the microsomal stability assay, thus leading
to the formation of improved GAC inhibitors.
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Figure 3: Variation in the ethylenediamine fragment during optimization led to IC50 activity to
increase 10x fold.
A different mode of ethylenediamine modification was used by Ko and coworkers, who
carried out H4 receptor antagonist pharmacophore screening to obtain hits for treating atopic
dermatitis7. A hit compound is a molecule that exhibits the desired activity at a given target
molecule in a screening assay. Compound 6 was among these initial hits and served as the basis
for continued optimization because it displayed good inhibitory activity (H4R IC50 >100 μM)
and selectivity over H3R (2.3 μM). However, this hit structure had poor metabolic stability and
modest potency. The team investigated changes in structure and alternative diamines to optimize
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these properties. The authors modified the methyl group to a chlorine group and changed
Triazole to a Tetrazole (Fig 3). This modification increases the potency of the H4 receptor
antagonist. In addition, the H4 receptor antagonist changes its alternative ethylenediamine
structure, thus leading to compound 8. Compound 8 dramatically improved inhibitory activity for
H4R, metabolic stability, and selectivity issues for other histamine receptors. Eventually, the
team derived compound 9 as a lead compound by introducing bromine instead of the chlorine
atom, which exhibits strong inhibitory activity against H4R and excellent selectivity over H3R.
Compound 9 is a highly potent and selective H4R antagonist without noticeable action on offtargets, including other histamine receptors and 5-HT3R, and exhibited an excellent
pharmacokinetic profile7.

Figure 4. Radiolabeling binding studies found and improved pKi, leading to compound 11.
A different approach to investigating conformationally restricted diamines and their
influence on affinity and selectivity for H4 receptor ligands was used by Bartole and colleagues8.
The human histamine H4 receptor (hH4R) is a promising target for treating immune system
disorders such as rheumatoid arthritis and bronchial asthma. Radioligand binding studies on
humans, mice, and rats were tested with different structures to improve H4 receptor binding.
After radiolabeling, binding studies with 10, the addition of an ethylenediamine structure showed
an improvement in the pKi value in the human receptors (Fig 4). The 11 compound structures at
the human, mouse, and rat histamine H4 receptors revealed comparable Kd values (41/17/22
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nM), low nonspecific binding (11−17%), and fast associations/dissociations8 (25−30 min).
Compound 11 has the potential for pharmacological studies on the H4R related to translational
animal models.

Figure 5. Active CLK inhibitors profiled from CGP-74514A led to the racemic CLK inhibitor
with improved IC50.
A triple exon-skipping luciferase reporter assay identified new CLK (CDC2-like protein
kinases) inhibitor pharmacophore hits. Increasing evidence links the CLKs to cancer with CLK1,
and CLK2 inhibition may benefit the treatment of triple-negative breast cancer9. The screening
identified several active hits, the most potent of which was CGP-74514A (12), which has been
reported to be cyclin-dependent kinases (CDKs) inhibitors. The CGP-74514A (12) shows
significant CLK inhibition and clear structure-activity relationships (SAR) at CLKs10. Using this

MAI 12
approach, the dual CLK2/CDK1 inhibitors CGP-74514A were optimized to yield more specific
CLK inhibitors SRI-29329 (13). Analogs of SRI-29329 with changed stereochemistry, such as
compound 15, increased CLKL IC50 (Fig 5).

Figure 6. Scaffold-hopping changed the ethylenediamine structure of the control core and its
stereochemistry, leading to increased ki activity of 5-HT6R
The serotonin type 6 receptor (5-HT6R) is a promising target for treating cognitive
impairments11. The scaffold-hopping approach around pyrroloquinoline derivatives CPPQ (16)
containing an ethylenediamine structure was applied to modify the central core structure for
developing 5-HT6R antagonists (Fig 6). This modification has changed the compound’s activity
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at 5-HT6R. The enantiomeric diversity was further evaluated for their selectivity over serotonin
receptors. A comparison of the binding mode of 18 and 19 demonstrated differences in the
orientation of the enantiomers of the ethylenediamine group. Studies revealed that the structural
requirements for higher affinity for the 5-HT6R lead to compound 19 with higher metabolic
stability and brain penetrant. This compound might be considered a new cognition-enhancing
agent.
Furthermore, rigid ethylenediamine structures can create an orexin receptor antagonist.
The orexins stimulate two distinct G-protein coupled receptors, orexin-1 (OX1R) and orexin-2
(OX2R), associated or selectively located in specific brain areas and expressed extensively
across the central nervous system. The role of orexin-1 receptors is believed to play a role in
addiction, panic, anxiety, and sleep. At the same time, the role of the orexin-2 receptor is an
essential modulator of sleep. The antagonist's inhibition of both OX1R and OX2R showed
effective treatment of insomnia12.

Figure 7. Structure of suvorexant commonly known as Belsomra (20). Suvorexant folds into a
twist-boat ring conformation (21).
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The development of small-molecule dual orexin receptor antagonists (DORAs)
demonstrated the importance of the orexin pathway for modulating sleep. The DORAs,
suvorexant (Belsomra), became the first orexin antagonist approved by the FDA to treat
insomnia13. To further optimize potent and brain penetrant DORAs, a scaffold-hopping approach
using known orexin ligands as a template searched for new lead structures. The restricted
ethylenediamine scaffold may contain structural properties that improve the binding affinity of
orexin receptor antagonists.
Suvorexant and several other orexins ligands fold into a twist-boat ring conformation,
with intramolecular π-stacking suggesting a low-energy conformation in orexin receptor
antagonists14. The U-shaped conformation 21 elicits bioactivity through orexin receptors with
improved antagonistic potency for the OX1 and OX2 receptors compared to open
conformation15. The orexin antagonist structure needs to fit the active conformation better of
orexin receptors for further optimization.
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Figure 8. The design of scaffolds for potential antagonists or agonists for OXR1/OXR2 for this
study.
This potential diamine rigid scaffold was derived by the ligand-based drug design
approach carrying the U-shaped conformation, with which known potent orexin antagonists,
such as suvorexant, are known to bind to the OXRs. The racemic bicyclic template will contain a
new restricted ethylenediamine structure unknown in the literature to be tested with OXRs (Fig
8). The various intermolecular interactions of the different enantiomers of the scaffold may form
a different morphology of the orexin receptors16.
This study hypothesizes that conformationally restricted ethylenediamine is used in drug
design as a focal point for further optimization. These results may offer new scaffolds unknown
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in the literature for exploration in drug design research. Moreover, the restricted ethylenediamine
scaffold containing known orexin receptor ligands may lead to orexin antagonists or agonists
with improved selectivity for OX1R and OX2R.

Discussion
Scheme 1

Figure 9. Scheme for retrosynthesis for the target diamine structure.
To achieve the rigid diamine scaffolds for potential antagonists or agonists for OXRs, the
retrosynthetic analysis for the target diamine 24 is shown in Figure 9. Starting from a
commercially available glycine derivative, the necessary carbons can be added and cyclized to
give ketone 26. The second nitrogen can be added in a stereoselective manner by reductive
amination with the expectation that the rigid fused natural of the bicyclic will provide the desired
stereochemistry. The rigidity of this racemic bicyclic template 25 displays the two nitrogen
atoms in a specific orientation with a particular angle between them. The two nitrogen atoms are
differentiated, permitting the installation of the R group pairs on each nitrogen in a particular
stereochemistry.
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Figure 10. Scheme of the synthesis conditions of the target diamine structure.
This bicyclic ketone is a known compound and was synthesized using the procedure of
Marko 198517. This cyclization was amenable to scale up and provided a good yield (70-85%) on
a milligram and gram scale.
Reductive amination using Na(OAc)3BH and benzylamine in dichloromethane at room
temperature furnished two ninhydrin positive products with similar Rf values on silica gel TLC.
Ninhydrin detects basic nitrogen atoms in molecules on a TLC plate. Purification of the crude
material was attempted to separate these two products; however, this proved to be difficult, and
this mixture was used without additional purification. The proton NMR spectrum and MS of the
mixture are shown below. The NMR spectrum suggests this TLC observation may be
misleading, as each signal can be assigned to specific protons in the target structure.
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Figure 11. 1H NMR and MS of compound 33,
The structure of the major product was assigned by a combination of 1H NMR and
LCMS spectra (Fig 11). The hydrogen signals were assigned and correlated to the major product
33. The LCMS spectrum showed the major product 33 with a molecular ion peak of 357 m/z.
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The minor unknown product gave a molecular ion peak at 379 m/z, indicating no amine
stereoisomer. Therefore, the structure of this minor compound is unknown.

Subsequent displacement and amidation reactions were tested with 33a. Introduction of
the 5-chlorobenzoxazole by displacement from 2,5-dichlorobenzooxazole in various solvents
with a range of bases and amidation using HATU, Et3N, and DMF with 2-(2, H,1,2,3 triazol-2yl) benzoic acid. Curiously, amidation of 33a was unsuccessful under different conditions.
Similarly, reactions to afford 34 from 33a were also unsuccessful with K3CO3 and Et3N in DMF,
CH3CN, and EtOH. As a result, the benzyl protecting group was removed prior to either amide
formation or chloro displacement from 2,5-dichlorobenzoxazole.
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Hydrogenation in ethanol at room temperature using Pearlman’s catalyst (Pd(OH)2 on
carbon) proved the most suitable catalyst and solvent. This reaction was limited in scale because
we observed decreased product yield if more than 1 gram of benzylamine was used. On a 1gram scale, this reaction can typically obtain a yield of 56% in crude form. However, the primary
amine product 36 is hard to purify due to high polarity, and as a result, the crude material was
used for future reactions.

Because this hydrogenation reaction was difficult to scale up, we briefly explored using
2,4-dimethoxylbenzylamine based on the anticipated ability to remove the electron-rich
dimethoxybenzyl group with trifluoroacetic acid. However, the crude dimethoxylbenzylamine
product 37 was hard to purify to homogeneity. Silica gel chromatography with different solvents
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and attempted recrystallization proved unsuccessful, and as a result, it was elected to attempt
removal of the dimethoxybenzyl group from crude 37 using trifluoroacetic acid.

Following the Nussbaumer et al. procedure18, removing the dimethoxybenzyl with
trifluoroacetic acid in DCM was successful in a small-scale (25mg) reaction. The 1H NMR of the
crude material 32b clearly showed product formation by comparison to the crude NMR of the
hydrogenation reaction 32. However, like with the hydrogenation reaction, scale-up proved
difficult. Different solvents, temperature, and stoichiometry were explored, and observed a
complex mixture of products and/or incomplete reactions. Attempted hydrogenation also failed,
and this effort was stopped.
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The amidation reaction following Chen et al.’s procedure19 was carried out using primary
amine 32d. After investigating a variety of coupling reagents and bases, the most efficient
combination was HATU, Et3N, in DMF with a slight excess of carboxylic acid (~1.1
equivalents). The reaction was successful, and the yield for compound 38 obtained was 40-55%.
The yield of this reaction is variable based on the use of crude material 32d.

Following the procedure of Boss et al., primary amine 32e was reacted with a known
orexin fragment, 2,5-dicholorobenzooxazole20. Using conditions such as K2CO3 in DMF at 60oC,
chloro displacement by 32e was unsuccessful. Different bases were investigated, such as K2CO3
and Et3N, and solvents such as THF, DMF, CH3N, and EtOH. Increasing the temperature from
60oC to 80oC provided an increase in product yield. The 1H NMR and LCMS are consistent with
the expected product 39. The displacement reaction was proven successful, with a 50% yield.

MAI 23

A second orexin building block, 2,6-dichlorobenzothiazole, was used under the same
conditions. Again, the reaction was successful, with a 50% yield.

With one of the nitrogen atoms containing orexin fragments in place, the focus is on
removing the tosyl amide protecting group to enable the second orexin building block
installation. Sonification of 35a using magnesium turnings in methanol was attempted to cleave
the tosyl protecting group21. Despite a couple of changes to improve the reaction conditions by
using different solvents and washed Mg, the reaction remained unsuccessful. This approach was
abandoned.
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Weisblat's experimental procedure22, hydrogen bromide in acetic acid with phenol
removed the tosyl protecting group in a small-scale (50mg) reaction. The 1H NMR and LCMS
spectra of compound 42 showed evidence for the deprotected product. Removal of HBr in acetic
acid on a larger scale proved challenging, making it difficult to scale this reaction up. The
polarity of the product 42 made purification by standard silica gel chromatography methods
difficult, leading us to investigate other routes for tosyl amide deprotection.

From the procedure reported by Yoshida et al. 23., the deprotection of the tosyl protection
group using diphenylphosphine anion was tested. The reaction was carried out with
diphenylphosphine and NaH in THF under N2 at -78oC for 2 hours. Following an exploratory
reaction on a small scale (25mg), TLC analysis showed a presence of a spot with an Rf value
similar to that observed following the HBr/phenol reaction mentioned above. The 1H NMR of
the crude product indicated the tosyl group had been removed. However, LCMS analysis of the
sample suggested a mass of 272g/mol rather than the expected 263g/mol for the deprotected
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product 43. Different conditions need further investigation because this deprotection reaction
may potentially remove the protecting group efficiently.

Scheme 2

Figure 12. Scheme for the target diamine structure with Boc protecting group.
The removal of the tosyl protecting group posed a challenge during this study. Thus, an
alternative route was considered using the tert-butyloxycarbonyl (Boc) protecting group. The
removal of the Boc protecting group can be easily removed using TFA. Several approaches and
reaction conditions were assessed to obtain the desired ketone 46.

Figure 13. Synthesis route for the targe structure 49.
Using the procedure of Robertiet al. procedure24, the synthesis of chloroacetamide 47 was
accomplished in 85% yield. Following chloro displacement with butenyl amine, the presumed
product 48 was unreactive in the presence of Boc-anhydride. This suggested product was not the
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desired secondary amine and instead was another unidentified compound. Because this issue
could not be easily solved, this scheme was abandoned.

Figure 14. Synthesis route for target structure 51.
This led to the investigation of an alternative approach beginning with Boc-protected
glycine. Following a similar route to Figure 9, we attempted to prepare acid chloride 50 using
oxalyl chloride in THF. However, we discovered that the attempted reaction of the product with
pyrrolidine to form amide 51 was unsuccessful. This may be due to either rapid decomposition of
the acid chloride or some other undesired reaction to furnish another byproduct. After a couple of
unsuccessful attempts to optimize pyrrolidine formation reaction, this route was discontinued.

Figure 15. Synthesis route for the target structure 55.
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Using Lijun’s (2013) procedure25, the formation of intermediates 52-54 was successful,
with a good overall yield of 70-80%. However, there was little to no reaction when adding the
pyrrolidine with compound 54, and this route was discontinued.
Overall, the inability to form the intermediate 45 showed that this Boc protecting route
was unsuccessful and incomplete. Further studies are needed to determine the optimal conditions
to synthesize intermediate 45. The succession of obtaining this intermediate will potentially form
the desired rigid ethylenediamine scaffold due to the ease of removing the Boc protecting group.

Conclusion and Future Research
For future consideration, the application of conformationally rigid ethylenediamine
scaffolds can potentially be studied for orexin antagonists for improved binding specificity and
potency. Exploring the racemic template of the ethylenediamine scaffolds may create an ideal
enantiomer(s) for the orexin ligand. This could bring potential drug targets for orexin receptors
to treat neurological diseases. However, some issues need to be addressed before testing the
ethylenediamine scaffold’s activity. These issues include continuing the investigation of
removing the tosyl protecting group and installing a second different orexin ligand fragment. In
addition, to further investigate the Boc protection group synthesis route as an alternative to
forming rigid ethylenediamine scaffolds. The synthesis of a new conformationally rigid
ethylenediamine derivative scaffold can create diverse orexin ligand drug designs template.
These studies may open new possibilities for conformationally rigid ethylenediamine synthesis
and its application to orexin receptor antagonist receptors.
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Results
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Liquid Chromatography-Mass Spectrometry (LC-MS)
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Experimental Method
All 1H NMR spectra were obtained using a 400MHz Bruker NMR Spectrometer in CDCl3, D6DMSO, or Acetone-6. The LCMS spectra were recorded using the Shimadzu LC-MS system in
methanol. Flash Chromatography was performed using silica gel columns and run using
CombiFlash Rf auto column. Thin Layer Chromatography (TLC) was conducted on
commercially available silica on alumina plates. The Thin Layer Chromatography (TLC)
visualization was done by PMA, KMnO4, Ninhydrin stains, and UV light (254 nm and 365 nm).
Compound 29
Np-Tosyl Glycine (15g, 65.5mmol), oxalyl chloride (16.9ml, 131 mmol), DMF, and
CH2Cl2(300ml) was stirred at RT for 2-3hrs to form an acid chloride. The reaction was
evaporated and put on the pump overnight.
Compound 30
Compound 29(15g, 60.7mmol), pyrrolidine (50.7ml, 607mmol), and THF (300ml) were mixed
overnight under N2. The next day, the reaction mixture was put under the rotavapor to evaporate
the THF. The reaction was diluted with 200mL of EtOAc and washed with HCL and brine. The
mixture was dried with Na2SO4 and concentrated using a rotavapor. Purification occurred on an
80g column and a 3:1 EtOAc: Hexane solvent system. The percent yield was 85%
Compound 31
Compound 30(14.5g, 51.42mmol), K2CO3 (4.3g, 30.93mmol), 4-Bromo-but-1ene (3.7ml,
36.12mmols), and DMF were stirred at RT overnight under N2. The reaction was diluted with
300ml distilled water and extracted with EtOAc. The extracted mixture was washed with brine,
dried with Na2SO4, and concentrated using a rotavapor. The percent yield was 79%
Compound 32
Under anhydrous conditions, triflic anhydride (366ul, 2.24mmol) was mixed with 1,2dichloroethane and 1,6-lutidine (173ul, 1.64mmol) was mixed with 1,2-dichloroethane in a
separate flask. The compound 7(500mg, 1.49mmol)/1,2-dichloroethane mixture was added
dropwise to the mixed triflic anhydride/1,2-dichloroethane mixture, and lastly, the 1,6-lutidine
mix was added. The reaction was heated to reflux and stirred under N2 for 2-3 hours. The
mixture was removed from heat and was cooled and concentrated using a rotavapor. 10mL of
chloroform and 1mL of acetone were added and stirred at reflux under N2 for 1 hour. The
mixture was cooled, and the chloroform was extracted. The remaining mixture was extracted
with DCM and combined with the extracted chloroform mixture. The organic mixture was
washed with brine, dried with Na2SO4, and concentrated using a rotavapor. Purification occurred
on a 12g column and a 1:1 EtOAc: Hexane solvent system. The percent yield was 76%.
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Compound 32b
Compound 37(25mg) was treated with TFA(2ml) in DCM overnight at reflux. The reaction
mixture was diluted with sodium bicarbonate and was extracted with DCM. The organic layer
was washed with brine, dried with Na2SO4, and concentrated using a rotavapor.
Compound 33
A mixture of compound 32 (100mg, 0.377mmol), benzylamine (58uL, 0.528mmol),
Na(OAC)3BH(112mg, 0.528mmol), a drop of HOac and CH2Cl2 was stirred at room temperature
for 2-3 hours. The reaction was then washed with sodium bicarbonate, and the organic layer was
washed with brine, dried with Na2SO4, and concentrated using a rotavapor. Purification occurred
with a 95:5 DCM: Methanol solvent system. The percent yield was 85%.
Compound 36
Pearlman’s catalyst (150mg, 30% of compound 32) was added to a dry glass vial, then 100ml of
ethanol was added, and lastly, intermediate 33(500mg, 1.40mmol). The mixture was stirred and
put on the hydrogenator overnight at RT. The reaction was filtered with diatomaceous earth and
concentrated using a rotavapor. The water was removed using ethanol and acetone washes. The
percent yield was 56%.
Compound 37
Compound 32 (250mg, 0.943mmol), was dissolved in CH2Cl2 and 2,4- dimethoxybenzylamine
(170ul, 1.13mmol), then Na(OAC)3BH(240mg, 1.13mmol) was added. The mixture was left to
stir at room temperature for 3 hours. The reaction mixture was washed with sodium bicarbonate,
and the organic layer was washed with brine, dried with Na2SO4, and concentrated using a
rotavapor. The percent yield was 63%.
Compound 38
A mixture of compound 32(360,1.35mmol), 5-methyl-2-(2H-1,2,3, triazol-2-yl) (282mg,
1.49mmol), HATU (566mg, 1.49mmol), Et3N (101.19ul, 1.49mmol) and DMF was stirred at RT
overnight. The reaction was diluted with brine and extracted with EtOAc, and the organic layer
was washed with brine, dried with Na2SO4, and concentrated using a rotavapor. Purification
occurred in a 1:1 EtOAc: Hexane solvent system. The percent yield was 45%.
Compound 39
A mixture of compound 32(360mg,1.35mmol), 2,5-Dichlorobenzooxazole(305mg,1.62mmol),
Et3N (226ul,1.62mmol), and DMF was stirred and heated to 80oC under N2 overnight. The
reaction was extracted with EtOAc, and the organic layer was washed with brine, dried with
Na2SO4, and concentrated using a rotavapor. Purification occurred in a 1:1 EtOAc: Hexane
solvent system. The percent yield was 55%.
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Compound 40
A mixture of compound 32(180mg, 0.80mmol),2,6-dichlorobenzothiazole (196mg,0.96mmol),
Et3N (134ul, 0.96mmol), and DMF was stirred and heated to 80oC under N2 overnight. The
reaction was extracted with EtOAc, and the organic layer was washed with brine, dried with
Na2SO4, and concentrated using a rotavapor. Purification occurred in a 1:1 EtOAc: Hexane
solvent system. The percent yield was 55%.
Compound 42
Compound 39(500mg, 1.2mmol) was dissolved in 15ml of HBR, and Phenol (475mg, 4.8mmol)
was added. The reaction stirred at 40oC for three days. The mixture was neutralized with sodium
bicarbonate until pH reached ~7. The reaction mixture was extracted with CH2Cl2, and the
organic layer was washed with brine, dried with Na2SO4, and concentrated using a rotavapor.
The percent yield was 63%
Compound 47
A mixture of pyrrolidine (671ul, 8.04mmol), DIPEA (4.3ml, 24.78mmol) in CH2Cl2(20ml) was
stirred at 0oC. Then chloroacetyl chloride (705ul, 8.85mmol) was added dropwise and was stirred
at 0oC for 1 hour. The reaction mixture was diluted with CH2Cl2 and washed with sodium
bicarbonate and HCl. The organic layer was washed with brine, dried with Na2SO4, and
concentrated using a rotavapor. The percent yield was 85%
Compound 48
A 0.3M mixture of 1-amino-3-butene hydrochloride, K2Co3 and THF was cooled in an iced bath
at 0oC. Then 0.5M solution of compound 47 and THF was added slowly to the reaction mixture
and stirred at 0oC for 2 hours and was warmed to room temperature and stirred for 1-3days. The
reaction mixture was diluted with sodium bicarbonate and was extracted with CH2Cl2. The
resulting organic layer was washed with brine, dried with Na2SO4, and concentrated using a
rotavapor. The percent yield was 79%
Compound 50
A mixture of N-Boc-Glycine (1g, 5.71mmol) in 20ml of THF with a drop of DMF and oxalyl
chloride (641ul, 7.42mmol) in a drop-by-drop and stirred for 2hours and concentrated and was
put on the vacuum pump overnight.
Compound 52
A mixture of glycine ethyl ester hydrochloride (30g, 214.8mmol) and CH3N was stirred in an ice
bath at 0oC, and Et3N (60ml, 450mmol) was added slowly drop by drop; the reaction was stirred
for 10 minutes at 0oC. Then a spoonful of KI and 4-Bromo-but-lene (24ml, 236.4mmol) was
added, and the reaction was left to stir at RT for 48hours under N2. The reaction was filtered
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through celite (Diatomaceous earth) and concentrated using a rotavapor. The percent yield was
79%
Compound 53
A mixture of compound 52(500mg, 3.18mmol), Et3N (576ul, 4.13mmol), and DMAP (77.7mg,
0.63mmol), and Di-tert-butyl dicarbonate (902.4mg, 4.13mmol) in CH2Cl2(10ml) was stirred
overnight. The reaction was diluted with CH2Cl2 and washed with HCl, and the organic layer was
washed with brine, dried with Na2SO4, and concentrated using a rotavapor. Purification occurred
on a 6:1 Hexane: EtOAc solvent system. The percent yield was 75%.
Compound 54
A mixture of compound 53(5.3g, 21.6mmol), NaOH (2.6g, 64.83mmol), in EtOH(100ml), and
H2O (25ml) was stirred at reflux for 2 hours. The reaction mixture was cooled and concentrated,
and drops of 2N HCL were added until a cloudy precipitate was formed. The mixture was
extracted with EtOAc, and the organic layer was washed with brine, dried with Na2SO4, and
concentrated using a rotavapor. The percent yield was 80%.
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